ESG

The first-ever Wegovy pill is now available via telehealth platform Ro, offering a cash-pay option that could revolutionize access to weight loss drugs.

Ormat Technologies and Switch sign a 20-year deal for geothermal energy, highlighting a crucial shift to reliable renewables for power-hungry AI data centers.

Aptar's 'Beat the Blink' technology, in partnership with Bausch + Lomb, promises to solve the age-old problem of inaccurate eye drop dosing.

The biotech firm faces a delisting threat after its equity turned negative. Can recent funding save its Nasdaq spot and its ambitious drug pipeline?

New rules will soon require frequent certificate renewals. A new partnership aims to help Aussie firms automate, as manual processes become impossible.

Adimab's stellar 2025 reveals its crucial role as the hidden tech platform driving drug discovery for giants like Lilly and Regeneron.

With new federal guidelines backing whole foods, programs delivering 'prescription produce' are proving they can cut healthcare costs and fight chronic disease.

A new report reveals surging anti-Americanism is damaging iconic brands. To survive, firms must swap patriotic ads for authentic local partnership.

A wellness company is calling out the supplement industry, claiming many popular shilajit gummies are ineffective, candy-like products. Here's what's real.

Construction begins on The Welton Centre, a landmark $25M facility set to fill a critical gap in compassionate end-of-life care for Canada's seventh-largest city.

A new drill-free cavity treatment is regenerating teeth, attracting Wall Street, and aiming to solve a global health crisis. This is the story of Curodont™.

Metta Lou Henderson and Steve Simenson are recognized for their transformative leadership and innovative patient care, shaping the future of pharmacy.

Cosmetics brand Sorevna is diving into the crowded bath and body sector, promising a revolutionary launch. But can its science-first approach succeed?

A new tech partnership connects real-time alerts with clinical records, promising a safer, more efficient future for senior living communities.

Juvena Therapeutics lands a $33.5M Series B and a major pharma deal to advance its AI-discovered regenerative drugs for neuromuscular diseases.

The clean-energy firm is commercializing its tech, securing a 10-year fuel deal in Portugal and deploying rail turbines as it seeks greater market access.

A new poll shows Iowans are furious over rising medical bills. With bipartisan anger mounting, the issue could reshape the 2026 political landscape.

As Vicenzaoro opens its sold-out 2026 show, the focus is on a new €60M pavilion, major industry trends, and its undisputed role as a global leader.

AI firm Owkin is leveraging NVIDIA's powerful computing to build a 'Biological Artificial Super Intelligence,' aiming to revolutionize drug discovery.

LyfeSci's acquisition of Clinically Media aims to fix the clinical trial bottleneck by integrating patient recruitment, promising faster, more diverse studies.